Blood Biomarker of Alzheimer's Disease (AD)
Public ClinicalTrials.gov record NCT03340571. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
mtDNA Damage in Alzheimer's Disease (AD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.
Study identification
- NCT ID
- NCT03340571
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 21 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 11, 2018
- Primary completion
- Jul 30, 2019
- Completion
- Jul 30, 2019
- Last update posted
- Oct 22, 2019
2018 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Duke University | Durham | North Carolina | 27710 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Alzheimer Disease trials
Other public records listing Alzheimer Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT06808984: Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease Recruiting
- NCT07787182: A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease Not yet recruiting
- NCT07787169: A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease Not yet recruiting
- NCT07763392: Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digital Testing Platform Across the Lifespan Recruiting
- NCT07756294: Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease Not yet recruiting
- NCT07633470: A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03340571, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2019 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03340571 live on ClinicalTrials.gov.